Pacritinib is primarily used in the treatment of myelofibrosis, a rare type of bone marrow cancer that leads to scarring in the marrow and disrupts normal blood cell production. It is especially beneficial for patients with low platelet counts, a common challenge in myelofibrosis that limits the use of other treatments. The compound works by inhibiting key signaling pathways, including JAK2 and IRAK1, which are involved in inflammation and abnormal cell proliferation. By targeting these pathways, pacritinib helps reduce spleen enlargement, alleviate symptoms such as fatigue and night sweats, and improve overall quality of life. It is being investigated in clinical trials for its efficacy in myeloproliferative disorders and certain types of lymphoma, showing potential in cases where inflammation and immune signaling play a central role.